Crescent Biopharma (CBIO) Capital Expenditures (2013 - 2026)
Crescent Biopharma (CBIO) reported Capital Expenditures of $147000.0 for Q1 2026, up 120.56% on a QoQ basis from -$715000.0 in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Capital Expenditures data on file, last reported at $147000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $147000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158000.0 (up 6137.66% YoY) and the FY2025 annual result came in at $11000.0, up 10.31% from the prior year.
- Capital Expenditures advanced to $147000.0 in Q1 2026 per CBIO's latest filing, from -$715000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $586000.0 in Q3 2025 and bottomed at -$715000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $7652.5 (2023), against an average of $19539.8.
- The widest annual swing landed in 2022, when Capital Expenditures plunged 99.96%; it then jumped 80000.0% in 2023.
- Tracing CBIO's Capital Expenditures over 5 years: stood at $1.0 in 2022, then jumped by 80000.0% to $801.0 in 2023, then surged by 216.23% to $2533.0 in 2024, then plunged by 28327.4% to -$715000.0 in 2025, then surged by 120.56% to $147000.0 in 2026.
- Per Business Quant, the three latest CBIO Capital Expenditures figures stand at $147000.0 (Q1 2026), -$715000.0 (Q4 2025), and $586000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Dec 31, 2025 | -715,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2024 | 2,533.00 |
| Jun 30, 2024 | 2,533.00 |
| Mar 31, 2024 | 7,439.00 |
| Mar 31, 2024 | 7,439.00 |
| Dec 31, 2023 | 801.00 |
| Dec 31, 2023 | 801.00 |
| Sep 30, 2023 | 7,866.00 |
| Sep 30, 2023 | 7,866.00 |
| Jun 30, 2023 | 10,530.00 |
| Jun 30, 2023 | 10,530.00 |
| Mar 31, 2023 | 2,197.00 |
| Mar 31, 2023 | 2,197.00 |
| Dec 31, 2022 | 1.00 |
| Dec 31, 2022 | 1.00 |
| Sep 30, 2022 | 2,483.00 |
| Sep 30, 2022 | 2,483.00 |
| Jun 30, 2022 | 41,186.00 |
| Jun 30, 2022 | 41,186.00 |
| Mar 31, 2022 | 40,521.00 |
| Mar 31, 2022 | 40,521.00 |
| Dec 31, 2021 | 2,447.00 |
| Dec 31, 2021 | 2,447.00 |
| Sep 30, 2021 | 4,334.00 |
| Sep 30, 2021 | 4,334.00 |
| Jun 30, 2021 | 5,102.00 |
| Jun 30, 2021 | 5,102.00 |
| Mar 31, 2021 | 3,060.00 |
| Mar 31, 2021 | 3,060.00 |
| Dec 31, 2020 | 57,819.00 |
| Dec 31, 2020 | 57,819.00 |
| Sep 30, 2020 | -3,831.00 |
| Sep 30, 2020 | -3,831.00 |
| Jun 30, 2020 | 6,383.00 |
| Jun 30, 2020 | 6,383.00 |
| Mar 31, 2020 | 8,136.00 |
| Mar 31, 2020 | 8,136.00 |
| Dec 31, 2019 | 12,357.00 |
| Dec 31, 2019 | 12,357.00 |
| Sep 30, 2019 | 18,266.00 |
| Sep 30, 2019 | 18,266.00 |
| Jun 30, 2019 | 74,767.00 |
| Jun 30, 2019 | 74,767.00 |
| Mar 31, 2019 | 39,538.00 |
| Mar 31, 2019 | 39,538.00 |
| Dec 31, 2018 | 57,004.00 |
| Dec 31, 2018 | 57,004.00 |
| Sep 30, 2018 | 26,560.00 |
| Sep 30, 2018 | 26,560.00 |
| Jun 30, 2018 | 25,436.00 |
| Jun 30, 2018 | 25,436.00 |
| Mar 31, 2018 | 16,618.00 |
| Mar 31, 2018 | 16,618.00 |
| Dec 31, 2017 | 34,247.00 |
| Dec 31, 2017 | 34,247.00 |
| Sep 30, 2017 | 32,687.00 |
| Sep 30, 2017 | 32,687.00 |
| Jun 30, 2017 | 164,204.00 |
| Jun 30, 2017 | 164,204.00 |
| Mar 31, 2017 | 62,969.00 |
| Mar 31, 2017 | 62,969.00 |
| Dec 31, 2016 | 674,873.00 |
| Dec 31, 2016 | 674,873.00 |
| Sep 30, 2016 | -10,921.00 |
| Sep 30, 2016 | -10,921.00 |
| Jun 30, 2016 | 22,980.00 |
| Jun 30, 2016 | 22,980.00 |
| Mar 31, 2016 | 17,270.00 |
| Mar 31, 2016 | 17,270.00 |
| Dec 31, 2015 | 3,227.00 |
| Dec 31, 2015 | 3,227.00 |
| Sep 30, 2015 | 58,392.00 |
| Sep 30, 2015 | 58,392.00 |
| Jun 30, 2015 | 204,636.00 |
| Jun 30, 2015 | 204,636.00 |
| Mar 31, 2015 | 2,339.00 |
| Mar 31, 2015 | 2,339.00 |
| Dec 31, 2014 | 14,865.00 |
| Dec 31, 2014 | 14,865.00 |
| Sep 30, 2014 | 102,001.00 |
| Sep 30, 2014 | 102,001.00 |
| Jun 30, 2014 | 81,817.00 |
| Jun 30, 2014 | 81,817.00 |
| Mar 31, 2014 | 13,920.00 |
| Mar 31, 2014 | 13,920.00 |
| Dec 31, 2013 | 12,430.00 |
| Dec 31, 2013 | 12,430.00 |
| Sep 30, 2013 | 39,169.00 |
| Sep 30, 2013 | 39,169.00 |
| Jun 30, 2013 | 23,668.00 |
| Jun 30, 2013 | 23,668.00 |
| Mar 31, 2013 | 6,824.00 |
| Mar 31, 2013 | 6,824.00 |